Arterial Peripheral Disease (Peripheral Artery Disease)

Overview

Peripheral artery disease (PAD), often called arterial peripheral disease, is a chronic condition in which the arteries that supply blood to the limbs—most commonly the legs—become narrowed or blocked by atherosclerotic plaque. The reduced blood flow can cause pain, cramping, skin changes, and, in severe cases, tissue loss.

Who it affects: PAD primarily affects adults over 50 years of age, but it can occur in younger individuals with significant risk factors (e.g., smokers, diabetics). According to the Centers for Disease Control and Prevention (CDC), more than 8.5 million people in the United States have PAD—about 1 in 12 adults over 40.

Global prevalence: The World Health Organization estimates that PAD affects roughly 200 million people worldwide, making it the third most common atherosclerotic disease after coronary artery disease and cerebrovascular disease ¹.

Symptoms

Symptoms vary according to the severity of arterial blockage and may be absent in early disease. Common manifestations include:

• Intermittent claudication – cramping, aching, or fatigue in the calves, thighs, or buttocks that begins with walking and resolves with rest.
• Rest pain – persistent pain in the foot or toes, especially when the leg is lowered (e.g., at night); indicates critical limb ischemia.
• Coldness or pallor of the affected limb.
• Reduced pulses – diminished or absent dorsalis pedis or posterior tibial pulses.
• Skin changes – thinning skin, shiny appearance, or hair loss on the legs.
• Ulcers or non‑healing wounds – often on the toes or forefoot; ulceration may be painless because of nerve damage.
• Weakness or fatigue in the leg after minimal activity.
• Leg swelling – can accompany advanced disease.

About 10–30 % of patients experience atypical leg pain or no pain at all, making routine screening important for high‑risk groups ².

Causes and Risk Factors

Underlying cause

PAD is most often caused by atherosclerosis—a buildup of cholesterol‑rich plaque in the arterial wall. Over time, the plaque enlarges, narrows the lumen, and can become unstable, leading to thrombosis (clot formation) that further impedes flow.

Major risk factors

• Smoking – the single biggest modifiable risk factor; smokers have a 2–4‑fold increased risk.
• Diabetes mellitus – accelerates atherosclerosis and can cause microvascular disease that compounds arterial loss.
• Hypertension – damages the arterial endothelium, facilitating plaque formation.
• Hyperlipidemia – elevated LDL‑cholesterol promotes plaque deposition.
• Age – prevalence rises sharply after age 50; >20 % of adults >80 have PAD.
• Family history of atherosclerotic disease.
• Chronic kidney disease and obesity.
• Physical inactivity – sedentary lifestyle reduces collateral circulation development.

Diagnosis

Diagnosis combines a detailed history, physical examination, and objective testing.

Clinical assessment

• Inspection for skin changes, ulcers, or muscle atrophy.
• Palpation of pedal pulses.
• Measurement of the ankle‑brachial index (ABI) – the ratio of systolic blood pressure at the ankle to that in the arm. An ABI ≤0.90 confirms PAD; 0.91–0.99 is borderline, and ≤0.40 indicates severe disease.

Imaging and functional tests

• Doppler ultrasound – non‑invasive, evaluates blood flow velocity and detects stenosis.
• Segmental pressure testing – measures pressure at multiple points along the leg.
• Computed tomography angiography (CTA) or magnetic resonance angiography (MRA) – visualize arterial anatomy, especially before interventions.
• Digital subtraction angiography (DSA) – the gold standard, reserved for cases where endovascular treatment is planned.
• Treadmill exercise testing – assesses functional limitation and can unmask abnormal ABI after exertion.

Treatment Options

Treatment is tiered: lifestyle modification, pharmacotherapy, then revascularization (endovascular or surgical) when symptoms persist.

Medication

• Antiplatelet agents – aspirin 75–162 mg daily or clopidogrel 75 mg daily reduce cardiovascular events (Class I recommendation, AHA/ACC).
• Statins – high‑intensity therapy (e.g., atorvastatin 40‑80 mg) lowers LDL and stabilizes plaque.
• ACE inhibitors or ARBs – improve endothelial function and reduce cardiovascular risk.
• cilostazol (100 mg BID) – improves walking distance in intermittent claudication but is contraindicated in heart failure.
• Rivaroxaban 2.5 mg BID** + aspirin – recent COMPASS trial data show reduced major limb events in PAD patients.

Lifestyle and risk‑factor control

• Complete smoking cessation (behavioral counseling + nicotine replacement or medications).
• Regular, supervised exercise program – 30‑45 minutes of walking, 3–5 times per week, improves collateral circulation.
• Weight loss to achieve BMI < 25 kg/m².
• Blood pressure < 130/80 mmHg; LDL‑C < 70 mg/dL for high‑risk individuals.
• Optimal glycemic control (HbA1c < 7 %).

Revascularization

Considered when lifestyle measures and medication fail to relieve functional limitation or when critical limb ischemia develops.

• Endovascular procedures – balloon angioplasty, stent placement, or atherectomy. Preferred for focal lesions and patients with high surgical risk.
• Open surgical bypass – femoral‑popliteal or femoral‑tibial bypass using autogenous vein or prosthetic graft; reserved for extensive disease or failed endovascular therapy.
• Hybrid approaches – combination of endovascular and limited surgical techniques.

Advanced care for critical limb ischemia

• Wound debridement and infection control.
• Cell‑based therapies or structured exercise under physician supervision.
• Amputation – last resort when necrosis or gangrene is irreversible.

Living with Arterial Peripheral Disease

Effective self‑management can maintain mobility and quality of life.

• Exercise program – use a “pain‑free” walking protocol: walk until mild calf discomfort, rest until pain subsides, repeat 5–10 times per session.
• Foot care – inspect feet daily for cracks, sores, or discoloration; keep nails trimmed; wear well‑fitting shoes.
• Medication adherence – set daily reminders or use pill organizers.
• Regular follow‑up – ABI check every 6–12 months; sooner if symptoms change.
• Vaccinations – flu and pneumococcal vaccines reduce risk of infections that can worsen PAD.
• Stress management – mindfulness, yoga, or counseling can improve overall cardiovascular health.

Prevention

Because PAD shares many risk factors with other atherosclerotic diseases, primary prevention mirrors general cardiovascular prevention:

• Never start smoking; if you smoke, quit immediately.
• Maintain a heart‑healthy diet rich in fruits, vegetables, whole grains, lean protein, and low in saturated fat and sodium (Mediterranean or DASH patterns).
• Engage in at least 150 minutes of moderate aerobic activity per week.
• Control blood pressure, cholesterol, and blood sugar per current guidelines.
• Screen high‑risk adults (≥ 50 years or < 50 with diabetes or smoking history) with an ABI.

Complications

If left untreated, PAD can progress to serious sequelae:

• Critical limb ischemia (CLI) – severe rest pain, non‑healing ulcers, or gangrene; high 1‑year mortality (≈ 20 %).
• Amputation – up to 5 % of PAD patients undergo major lower‑extremity amputation.
• Cardiovascular events – PAD is a marker of systemic atherosclerosis; patients have a 2‑ to 3‑fold higher risk of myocardial infarction and stroke.
• Reduced functional capacity – progressive walking limitation contributes to frailty and loss of independence.

When to Seek Emergency Care

References

1. World Health Organization. Peripheral artery disease (PAD). WHO Fact Sheet, 2023.
2. American Heart Association & American College of Cardiology. 2024 Guideline for the Management of Patients With Peripheral Artery Disease. Circulation. 2024;149:e539‑e567.
3. U.S. Centers for Disease Control and Prevention. Peripheral Artery Disease (PAD) Fact Sheet. Updated 2022.
4. Mayo Clinic. Peripheral artery disease – symptoms and causes. Accessed May 2026.
5. National Institute for Health and Care Excellence (NICE). Peripheral arterial disease: diagnosis and management. NG 154, 2024.